Key points from article :
Booster Therapeutics, a biotech company based in Berlin, has launched with $15 million in seed funding to develop new medicines that activate proteasomes, the cell’s natural protein-degradation system. These "proteasome activator medicines" are designed to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s, which are linked to the accumulation of toxic proteins in cells. Booster's approach targets the “20S” proteasome, offering a potential solution to complex diseases by enhancing the body’s ability to naturally clear damaged proteins without the need for tagging them.
As people age, proteasome function declines, leading to the build-up of harmful proteins that contribute to various age-related diseases. Traditional methods have struggled to address multiple protein dysfunctions, but Booster's strategy aims to restore proteasome activity, which could help re-establish protein balance and improve cellular health. This innovation holds promise for extending healthy lifespan by tackling the root causes of cellular stress associated with ageing and disease.
With support from investors like Apollo Health Ventures and Novo Holdings, Booster is building a pipeline of therapeutic compounds targeting neurodegenerative diseases and other conditions. If successful, their approach could revolutionize the treatment of these challenging diseases by addressing their underlying causes at a cellular level.
